CATEGORY AND TAGS:
ARA 290 Peptide raw powder, raw ARA290 peptide, ARA 290 Dosage Dose, buy ARA-290 2mg, ARA-290 5mg blue top, ARA290 10mg red top, ARA-290 cycle, ARA-290 factory price, research chemical ARA-290 peptide, ARA-290 10vials, where to buy ARA 290, ARA 290 peptide supplier, ARA-290 online store, buy ARA290 Canada, ARA 290 Poland, ARA-290 USA, human growth peptide ARA290, ARA 290 manufacturer, ARA 290 raw powder for sale, ARA 290 effects, ARA 290 fat loss
ARA-290 Specifications
CAS: 1208243-50-8
MF: C51H84N16O21
MW: 1257.31
EINECS: 200-001-8
Purity: 99%
ARA-290 Description
ARA-290 is a small peptide derived from the helix beta domain of erythropoietin (EPO).EPO has long been know to exhibit actions beyond the stimulation of red blood cell production in bonemarrow.The glycoprotein, which is made in the kidney, has been found to stimulate blood vesselgrowth, promote cell survival, alter blood pressure, and produce neuroprotective effects in diabeticneuropathy.ARA-290 offers the neuroprotective and pain relieving effects of EPO without stimulating red blood ell production. ARA-290 has completed phase ll trials and is in preparation to enter phase ll trials for a variety of applications in diabetes and the autoimmune sarcoidosis. Right now, the peptide is of active interest for its ability to control neuropathic pain,but it is also under investigation as a potential stimulator of wound repair in chronic diabetes, as an immune modulatory drug, and as a potential treatment for systemic lupus erythematosus(lupus or SLE).
ARA-290 Application:
1.Blood Vessel Health
Retinal ischemia, which results from a number of disease processes, is a leading cause of blindness in industrialized nations. The ability to protect retinal epithelial cells from injury or the ability to promote their regeneration following an insult, could go a long way to reducing disease burden. Research in mice indicates that ARA-290 can protect endothelial colony forming cells against the ravages of inflammation. In so doing,ARA-290 prolongs cell survival and helps endothelial colony forming cells (ECFCs) to repair and rebuild blood vessels.
Other studies in mice show that ARA-290 enhances the proliferation, migration, and longevity of ECFCs throughout the vasculature. lt also appears that ARA-290 boosts the homing ability of ECFCs, helping them to better target areas of the vasculature that are in need of repair. There is hope that this function can not only help to boost the effects of endogenous ECFCs, but can help to improve the ability of transplanted ECFCs to repair vasculature and restore blood flow to
ischemic tissue. f successful in the case of ECFC transplants,ARA-290 could open up a whole new area of medical therapy allowing functional cells to be transplanted successfully for tissue repair,hormone production, protein building, and more.
2.Reducing Inflamatory Cytokines
Research in mice shows that ARA-290 can hep to promote the survival of transplanted islet cells by inhibiting macrophage activation. For years, the treatment of diabetes via the transplantation of healthy insulin-producing islet cells has been the holy grail of endocrinology. Islet cells, unlike exogenous insulin, provide a much more physiologic control of blood sugar and therefore drastically reduce the complications often seen even in well-controlled diabetes.Unfortunately,islet cells do not survive transplantation for long and thus the procedure has been all but abandoned. With the development of ARA-290, however, that may be changing.Studies in mice have revealed that the peptides ability to suppress inflammatory cytokines like IL-6,IL-12, and TNF-alpha drastically prolongs the survival of transplanted islet cells
The ability of ARA-290 to protect against normal inflammatory responses appears to be mediated through the binding of the peptide to the tissue-protective receptor (TPR), boosting tissue protection and helping to regulate the immune system. EPO also binds to the TPR, but has a number of cardiovascular and hematopoietic side effects that have made it untenable as a treatment in many if not most settings.By binding to the TPR and not promoting some of the other effects of EPO, peptides like ARA-290 help to reduce apoptosis and cut back on the levels of harmful inflammatory cytokines.The net results are tissue protection and improved tissue regeneration. Both of these features lead to reduced morbidity and mortality, fast wound healing,reduced scar formation, and fast post-injury recovery of function
